EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Fluoroquinolones and rifampin combination in the backdrop of heteroresistant tuberculosis

Vanessa B Vogensen, Sanjay Singh, Christopher J Allende, David M Engelthaler iD, Gunavanthi D Boorgula, Tania A Thomas, Marieke G G Sturkenboom iD, Onno W Akkerman iD, Tawanda Gumbo iD, Shashikant Srivastava iD

Antimicrobial Agents and Chemotherapy · 2025

DOI: 10.1128/aac.01084-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Vanessa B Vogensen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Diseases and Tuberculosis, University Medical Center Groningen, Groningen, the Netherlands. Hauptthemen laut MEDLINE: Rifampin, Mycobacterium tuberculosis, Antitubercular Agents, Fluoroquinolones. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NICHD NIH HHS, HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The impact of heteroresistance on tuberculosis (TB) treatment outcomes is unclear, as is the role of different rifampin and isoniazid exposures on developing resistance mutations. Hollow fiber system model of TB (HFS-TB) units were inoculated with drug-susceptible Mycobacterium tuberculosis ( Mtb ) and treated with isoniazid and rifampin exposure identified in a clinical trial as leading to treatment failure and acquired drug resistance. Systems were sampled for drug concentration measurements, estimation of total and drug-resistant Mtb , and small molecule overlapping reads (SMOR) analysis for the detection of heteroresistance. In the second HFS-TB study, systems were inoculated with an isoniazid-resistant clinical strain and treated with various combinations of isoniazid, rifampin, moxifloxacin, and levofloxacin for 28 days. Linear regression and exponential decline models were used for data analysis. Suboptimal isoniazid and rifampin exposures failed to kill drug-susceptible Mtb in the HFS-TB. Standard susceptibility methods failed to detect drug resistance, but SMOR detected isoniazid and rifampin heteroresistance, as well as fluoroquinolone, to which bacilli were not exposed. rpoB mutations arising from low rifampin exposures were Q513K and H526N, whereas those from regimen adequate rifampin but low isoniazid concentrations were S531L. Moxifloxacin-rifampin combination sterilized the HFS-TB units inoculated with the isoniazid-resistant Mtb in 14 days compared with 21 days of treatment with levofloxacin-rifampin, with no further emergence of drug resistance. Early detection of isoniazid and rifampin heteroresistance could provide an opportunity to individualize the therapy and protect fluoroquinolones when added to the MDR-TB treatment regimen.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RifampinMycobacterium tuberculosisAntitubercular AgentsFluoroquinolonesTuberculosis, Multidrug-ResistantIsoniazidMicrobial Sensitivity TestsMoxifloxacinHumansLevofloxacinMutationDrug Therapy, CombinationDrug Resistance, Multiple, Bacterial

Stichwörter der Autor:innen

Mycobacterium tuberculosisdrug-resistancefluoroquinoloneshollow fiber modelpharmacokinetics/pharmacodynamics

Substanzen

RifampinAntitubercular AgentsFluoroquinolonesIsoniazidMoxifloxacinLevofloxacin

Autor:innen und Institutionen

  • Department of Pulmonary Diseases and Tuberculosis, University Medical Center Groningen, Groningen, the Netherlands.
  • Division of Infectious Diseases, Department of Medicine, University of Texas at Tyler School of Medicine, Tyler, Texas, USA.
  • Translational Genomics Research Institute, Flagstaff, Arizona, USA.
  • Department of Medicine, University of Virginia, Charlottesville, Virginia, USA.
  • Department of Clinical Pharmacy and Pharmacology, University Medical Centrum Groningen, University of Groningen, Groningen, the Netherlands.
  • TB Center Beatrixoord, University Medical Center Groningen, Groningen, the Netherlands.

ORCID-Profile: David M Engelthaler, Marieke G G Sturkenboom, Onno W Akkerman, Tawanda Gumbo, Shashikant Srivastava

Förderung

  • NIAID NIH HHS
  • NICHD NIH HHS
  • HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
  • HHS | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
  • University of Texas System (UT)

Zitieren

APA

Vogensen, V. B., Singh, S., Allende, C. J., Engelthaler, D. M., Boorgula, G. D., Thomas, T. A., Sturkenboom, M. G. G., Akkerman, O. W., Gumbo, T., & Srivastava, S. (2025). Fluoroquinolones and rifampin combination in the backdrop of heteroresistant tuberculosis. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01084-24

Vancouver

Vogensen VB, Singh S, Allende CJ, Engelthaler DM, Boorgula GD, Thomas TA, et al. Fluoroquinolones and rifampin combination in the backdrop of heteroresistant tuberculosis. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.01084-24

BibTeX
@article{Vogensen2025,
  author = {Vogensen, Vanessa B and Singh, Sanjay and Allende, Christopher J and Engelthaler, David M and Boorgula, Gunavanthi D and Thomas, Tania A and Sturkenboom, Marieke G G and Akkerman, Onno W and Gumbo, Tawanda and Srivastava, Shashikant},
  title = {Fluoroquinolones and rifampin combination in the backdrop of heteroresistant tuberculosis},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  doi = {10.1128/aac.01084-24}
}
Kostenlos starten →